Andrea L. Zaenglein

Andrea L. Zaenglein

Auto-generated profile, based on publicly available information

Andrea L. Zaenglein

Departments of Dermatology and Pediatrics, Penn State/ Hershey Medical Center, Penn State Children's Hospital, Hershey, PA, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Pediatric Dermatology
Verified
Journal Article
Open access
PDF file
AZAndrea L. Zaenglein
Andrea L. Zaenglein
MLMoise L. Levy
Moise L. Levy
NSNicole S. Stefanko
Nicole S. Stefanko
LBLatanya T. Benjamin
Latanya T. Benjamin
ABAnna L. Bruckner
Anna L. Bruckner
PGPeDRA Use of Retinoids in Ichthyosis Work Group
PeDRA Use of Retinoids in Ichthyosis Work Group
Topical and systemic retinoids have long been used in the treatment of ichthyoses and other disorders of cornification. Due to the need for long‐term use of retinoids for these disorders, often beginning in childhood, numerous clinical concerns must be considered. Systemic retinoids have known side effects involving bone and eye. Additionally, potential psychiatric and cardiovascular effects need to be considered. Contraceptive concerns, as well as the additive cardiovascular and bone effects of systemic retinoid use with hormonal contraception must also be deliberated for patients of childbearing potential. The Pediatric Dermatology Research Alliance (PeDRA) Use of Retinoids in Ichthyosis Work Group was formed to address these issues and to establish best practices regarding the use of retinoids in ichthyoses based on available evidence and expert opinion.

13 June 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
ADAnnyella Douglas
Annyella Douglas
AZAndrea L. Zaenglein
Andrea L. Zaenglein

1 December 2019 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
CLCarolyn Lou
Carolyn Lou
NMNandita Mitra
Nandita Mitra
BWBradley Wubbenhorst
Bradley Wubbenhorst
KDKurt D'ANdrea
Kurt D'ANdrea
OHOle Hoffstad
Ole Hoffstad
DMDavid J. Margolis
David J. Margolis

1 March 2020 in Pediatric Annals
Verified
Journal Article
Closed access
PDF file
KBKatherine Berry
Katherine Berry
JLJordan Lim
Jordan Lim
AZAndrea L. Zaenglein
Andrea L. Zaenglein
Acne is the most common skin condition observed in adolescent and preadolescent patients. Pediatric providers are on the forefront of managing the disease, often as a secondary concern in a busy practice. Therefore, every provider needs to have an acne treatment plan that is effective, easy to communicate, and simple to follow. This article provides treatment rationale and guidelines-based recommendations for the initial treatment of acne, tips for troubleshooting any side effects, and a plan for subsequent follow-up to maintain good control. [ Pediatr Ann . 2020;49(3):e109–e115.]

1 August 2021 in Human Immunology
Verified
Journal Article
Closed access
DMD.J. Margolis
D.J. Margolis
NMN. Mitra
N. Mitra
JDJ.L. Duke
J.L. Duke
RBR. Berna
R. Berna
JMJ.D. Margolis
J.D. Margolis
Dimitri MonosDimitri Monos
Dimitri Monos

31 March 2023 in Experimental Dermatology
Verified
Journal Article
Open access
ZNZachary T. Nolan
Zachary T. Nolan
KBKalins Banerjee
Kalins Banerjee
ZCZhaoyuan Cong
Zhaoyuan Cong
SGSamantha L. Gettle
Samantha L. Gettle
ALAmy L. Longenecker
Amy L. Longenecker
ANAmanda M. Nelson
Amanda M. Nelson
There are no drugs as effective as isotretinoin for acne. Deciphering the changes in the microbiome induced by isotretinoin in the pilosebaceous follicle of successfully treated patients can pave the way to identify novel therapeutic alternatives. We determined how the follicular microbiome changes with isotretinoin and identified which alterations correlate with a successful treatment response. Whole genome sequencing was done on casts from facial follicles of acne patients sampled before, during and after isotretinoin treatment. Alterations in the microbiome were assessed and correlated with treatment response at 20 weeks as defined as a 2‐grade improvement in global assessment score. We investigated the α‐diversity, β‐diversity, relative abundance of individual taxa, Cutibacterium acnes strain composition and bacterial metabolic profiles with a computational approach. We found that increased β‐diversity of the microbiome coincides with a successful treatment response to isotretinoin at 20 weeks. Isotretinoin selectively altered C. acnes strain diversity in SLST A and D clusters, with increased diversity in D1 strains correlating with a successful clinical response. Isotretinoin significantly decreased the prevalence of KEGG Ontology (KO) terms associated with four distinct metabolic pathways inferring that follicular microbes may have limited capacity for growth or survival following treatment. Importantly, these alterations in microbial composition or metabolic profiles were not observed in patients that failed to achieve a successful response at 20 weeks. Alternative approaches to recapitulate this shift in the balance of C. acnes strains and microbiome metabolic function within the follicle may be beneficial in the future treatment of acne.